Mackay Shields LLC Exelixis, Inc. Transaction History

Mackay Shields LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $6.22 Million - $8.86 Million	-346,461 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $8.06 Million - $9.9 Million	-392,687 Reduced 53.13%	346,461 $7.83 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $1.22 Million - $1.65 Million	66,459 Added 9.88%	739,148 $14.8 Million
Q3 2020 Nov 04, 2020	SELL	$20.67 - $26.94 $1.98 Million - $2.58 Million	-95,627 Reduced 12.45%	672,689 $16.4 Million
Q2 2020 Jul 31, 2020	BUY	$16.46 - $27.42 $1.9 Million - $3.16 Million	115,376 Added 17.67%	768,316 $18.2 Million
Q1 2020 May 08, 2020	BUY	$14.46 - $21.8 $6.04 Million - $9.1 Million	417,596 Added 177.44%	652,940 $11.2 Million
Q4 2019 Feb 11, 2020	BUY	$15.15 - $18.89 $353,419 - $440,665	23,328 Added 11.0%	235,344 $4.15 Million
Q3 2019 Nov 01, 2019	BUY	$17.68 - $22.65 $3.75 Million - $4.8 Million	212,016 New	212,016 $3.75 Million
Q2 2019 Aug 13, 2019	SELL	$18.93 - $24.75 $1.51 Million - $1.98 Million	-79,938 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $1.57 Million - $1.98 Million	79,938 New	79,938 $1.9 Million

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.